Finotti Alessia Stampa
RESPONSABILE DELLA U. O.

Cognome e Nome Finotti Alessia
Qualifica Ricercatore a tempo determinato di tipo B (RTD-B)
Dipartimento Scienze della Vita e Biotecnologie
Settore Scientifico Disciplinare BIO/10
E-mail Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo.
Tel 0532-974510

PERSONALE STRUTTURATO

Cognome e Nome Ferrari Davide
Qualifica
Professore Associato
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara
Cognome e Nome Ferraresi Paolo
Qualifica Tecnico
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara
Cognome e Nome Gambari Roberto
Qualifica Eminente Studioso
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara

PERSONALE NON STRUTTURATO

Cognome e Nome Zuccato Cristina
Qualifica Titolare assegno di ricerca
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza
Università di Ferrara
Cognome e Nome Gasparello Jessica
Qualifica Titolare di borsa di Studio
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza
Università di Ferrara
Cognome e Nome Cosenza Lucia Carmela
Qualifica Titolare assegno di ricerca
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara
Cognome e Nome Zurlo Matteo
Qualifica Dottorando
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara
Cognome e Nome Papi Chiara
Qualifica Dottornada
Dipartimento Scienze della Vita e Biotecnologie
Ente di appartenenza Università di Ferrara

LINEE DI RICERCA

-Targeting of the microRNA/transcription factor network combined with a PNA-based antisense approach for SARS-CoV-2 for tackling viral expression and the cytokine storm of COVID-19.

-Gene editing in β-thalassemia, Shwachman-Diamond Syndrome and cystic fibrosis.

-Drug repurposing in β-thalassemia and cystic fibrosis as a useful strategy to develop sustainable therapeutic approaches for rare diseases.

-From laboratory research to “orphan drug designation” for β-thalassemia and cystic fibrosis.

-Ex vivo and in vivo effects of Sirolimus in β-thalassemia: from pre-clinical research to clinical trials.

-Prediction of the disease severity and the clinical outcome by studying fetal haemoglobin related BCL11A, MYB, LYAR and XmnI polymorphisms in β-thalassemia.

-Targeting BCL11A for gamma-globin mRNA induction in erythroid precursor cells from β-thalassemia patients.

-Identification of novel compounds as inducers of erythroid differentiation for the development of therapeutic protocols for β-thalassemia.

-Development, characterization and maintenance of cellular biobanks for β-thalassemia.

-Study of microRNAs involved in human genetic pathologies for the development of new approaches of microRNA targeting and miRNA replacement.

-MicroRNA therapeutics for the development of protocols aimed at the rescue of CFTR biological activity in cystic fibrosis cells: increase CFTR expression by peptide-nucleic acid targeting microRNAs regulators of CFTR and NHERF1.

-Development of novel therapeutic strategies using microRNA and combined approaches in oncology.

-Novel strategies for the delivery of miRNAs and PNAs: calixarenes.

-Induction of apoptosis temozolomide-resistant glioma cell lines using combined approaches.

-Studies on the relationship between transcription factors and microRNA expression in cystic fibrosis.

-Development of a Peptide Nucleic Acid (PNA)-based strategy to inhibit proliferation and anti-inflammatory activity of Pseudomonas aeruginosa.

-Molecular analysis of peripheral blood (liquid biopsy) biomarkers (circulating microRNAs) in cancer patients.

-Proteomics and transcriptomics (microRNA and mRNA NGS) analysis in genetic diseases (cystic fibrosis, β-thalassemia, Shwachman-Diamond Syndrome) and in neoplastic pathologies (glioblastoma, colon cancer).


TECNOLOGIE IN POSSESSO DELL'U. O.

Procaryotic and eukaryotic cell cultures

Primary mammalian cell cultures

Genome editing with CRISPR-Cas9

Reporter gene assays

Secretomic Analysis

Nucleic acid quantification: qRT-PCR, ddPCR

Flow cytometry

Microscopy and Live Cell Screening Systems

SPR technology

HPLC


STRUMENTAZIONE

Denominazione
Struttura ove la strumentazione è allocata
Responsabile della strumentazione
BioStation Model Cell-S1 Dipartimento di Scienze della Vita e Biotecnologie Alessia Finotti
Biacore-X100 Dipartimento di Scienze della Vita e Biotecnologie Roberto Gambari/Alessia finotti
HPLC System Gold 166-Detector and 126-Solvent Module Dipartimento di Scienze della Vita e Biotecnologie Alessia Finotti

PUBBLICAZIONI

Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.

Gasparello J, D'Aversa E, Papi C, Gambari L, Grigolo B, Borgatti M, Finotti A, Gambari R.

Phytomedicine. 2021 May 4;87:153583. doi: 10.1016/j.phymed.2021.153583.

Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients.

Cosenza LC, Gasparello J, Romanini N, Zurlo M, Zuccato C, Gambari R, Finotti A.

Mol Ther Methods Clin Dev. 2021 Apr 3;21:507-523. doi: 10.1016/j.omtm.2021.03.025. eCollection 2021

Delivery of Peptide Nucleic Acids Using an Argininocalix[4]arene as Vector.

Finotti A, Gasparello J, Casnati A, Corradini R, Gambari R, Sansone F.

Methods Mol Biol. 2021;2211:123-143. doi: 10.1007/978-1-0716-0943-9_10.

Treatment of human airway epithelial Calu-3 cells with a peptide-nucleic acid (PNA) targeting the microRNA miR-101-3p is associated with increased expression of the cystic fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Fabbri E, Tamanini A, Jakova T, Gasparello J, Manicardi A, Corradini R, Finotti A, Borgatti M, Lampronti I, Munari S, Dechecchi MC, Cabrini G, Gambari R.

Eur J Med Chem. 2021 Jan 1;209:112876. doi: 10.1016/j.ejmech.2020.112876.

A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery.

Gasparello J, Papi C, Allegretti M, Giordani E, Carboni F, Zazza S, Pescarmona E, Romania P, Giacomini P, Scapoli C, Gambari R, Finotti A.

Cancers (Basel). 2020 Aug 25;12(9):2410. doi: 10.3390/cancers12092410.

High Levels of Apoptosis Are Induced in the Human Colon Cancer HT-29 Cell Line by Co-Administration of Sulforaphane and a Peptide Nucleic Acid Targeting miR-15b-5p.

Gasparello J, Gambari L, Papi C, Rozzi A, Manicardi A, Corradini R, Gambari R, Finotti A.

Nucleic Acid Ther. 2020 Jun;30(3):164-174. doi: 10.1089/nat.2019.0825.

BCL11A mRNA Targeting by miR-210: A Possible Network Regulating γ-Globin Gene Expression.

Gasparello J, Fabbri E, Bianchi N, Breveglieri G, Zuccato C, Borgatti M, Gambari R, Finotti A.

Int J Mol Sci. 2017 Nov 26;18(12):2530

Purinergic Signaling in Controlling Macrophage and T Cell Functions During Atherosclerosis Development.

Ferrari D, la Sala A, Milani D, Celeghini C, Casciano F.

Front Immunol. 2021 Feb 16;11:617804. doi: 10.3389/fimmu.2020.617804

Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity?

Ferrari D, Locatelli M, Briguglio M, Lombardi G.

Cell Biochem Funct. 2021 Jan;39(1):35-47. doi: 10.1002/cbf.3597

Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency.

Ferraresi P, Balestra D, Guittard C, Buthiau D, Pan-Petesh B, Maestri I, Farah R, Pinotti M, Giansily-Blaizot M.

Haematologica. 2020 Mar;105(3):829-837. doi: 10.3324/haematol.2019.217539.


DOTTORATI DI RICERCA

Componente U.O. Dottorato di Ricerca Coordinatore Sede
Alessia Finotti
Scienze Biomediche e Biotecnologiche
Prof. Pinton Paolo
Ferrara

CONGRESSI C.I.B.

Congressi Partecipazione
CNB4

CNB5

CNB6

CNB7

CNB8

CNB9
CNB10